Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Journal for Immunotherapy of Cancer|February 23, 2022
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysisSiming Li, Xiaowen Wu, Xieqiao Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial CarcinomaXinan Sheng, Xieqiao Yan, Lin Wang, et al.
BMC Cancer|February 7, 2023
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II studyChuanliang Cui, Yu Chen, Zhiguo Luo, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insightsXuan Wang, Hui Tian, Zhihong Chi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2018
Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 studyXinan Sheng, Dengfeng Cao, Jianlin Yuan, et al.
The Oncologist|October 17, 2024
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinomaBixia Tang, Jun Xiao, Zhihong Chi, et al.
Frontiers in Oncology|June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-Ad hoc Analyses of Pooled Data From Two Clinical TrialsXue Bai, Jie Dai, Caili Li, et al.
Frontiers in Oncology|September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa TrialLili Mao, Ya Ding, Xue Bai, et al.
Signal Transduction and Targeted Therapy|November 21, 2024
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trialJiayong Liu, Xuan Wang, Zhongwu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2017
Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted TherapyYan Kong, Xinan Sheng, Xiaowen Wu, et al.
Pageof 13